Margetuximab (Margenza) Chinese instructions

1. Indications

Margetuximab (Margenza) is an innovative drug used to treat a specific type of breast cancer, HER2 (human epidermal growth factor receptor 2)-positive breast cancer. Indications include the following conditions:

For the treatment ofHER2positive breast cancer in adult women whose disease is advanced or has relapsed and who have received other prior antiHER2 therapies.

2. Mechanism of action

The mechanism of action of margetuximab mainly involves the following aspects:

1.Margituximab is a monoclonal antibody specifically designed to inhibit the growth ofHER2positive breast cancer cells.

2.This drug inhibits the growth and division of cancer cells by binding to the HER2 receptor and preventing its activation.

3.Margetuximab can also enhance the immune response by prompting the immune system to attack cancer cells more effectively.

3. Pharmacology

1.Margituximab slows down disease progression by inhibiting the growth and division ofHER2positive breast cancer cells.

2.It can also help the body fight off cancer cells more effectively by enhancing the immune system.

3.The effects of the drug may begin to appear within a few weeks of treatment, but the specific effects will vary from individual to individual.

4. Dosage and usage

1.Margetuximab is usually given as an intravenous injection every three weeks.

2.Dosage will vary based on the patient's weight and specific treatment plan.

3.Treatment should be formulated and supervised by a professional physician based on the patient's specific situation.

5. Side Effects

The use of margituximab may be associated with the following common side effects: fatigue, diarrhea, vomiting, skin rash, sore throat, bone pain, increased risk of fracture, etc.

6. Warnings and Precautions

1.Patients should monitor closely and report any discomfort or unusual symptoms to their doctor.

2.Margituximab may cause serious skin reactions, such as blisters or rashes, which should be reported to your doctor immediately.

3.Patients may feel fatigued during treatment and should avoid driving or engaging in tasks that require alertness.

4.Women should use contraceptive measures during treatment because margituximab may cause harm to the fetus.

7. Contraindications

1.Patients who are allergic to any component of margetuximab.

2.Pregnant and lactating women.

3.Patients with severe heart problems or high blood pressure during treatment.

8. Drug interactions

1Margituximab may interact with other drugs, so patients should provide their doctor with a detailed drug list to ensure the safety and effectiveness of treatment.

2.Combined use with other HER2 inhibitors or anti-cancer drugs may affect efficacy or increase the risk of adverse reactions.

9. Medication for Special Populations

The safety and effectiveness of macituximab have not been established in children, adolescents, and patients > 65 years of age.

In patients with impaired liver or kidney function, medication may need to be adjusted, and doctors will evaluate the situation on a case-by-case basis.

In conclusion, margituximab is an innovative drug that is expected to improve the survival rate and quality of life of patients with HER2 positive breast cancer. However, patients must consult a professional physician before use and follow medical instructions to ensure safe and effective treatment. This leaflet provides basic information but should not replace your doctor's advice and guidance.